• Home
  • NEW DAY MEDICINE
  • 2 (34/1) 2021
  • 38 – 2 (34/1) 2021 — Klichova F.K, Musayeva D.M. — SPECIFICITIES OF GENOTYPIC VARIATIONS OF CYP2C19 GENE WHILE PEPTIC ULCER TREATMENT

38 – 2 (34/1) 2021 — Klichova F.K, Musayeva D.M. — SPECIFICITIES OF GENOTYPIC VARIATIONS OF CYP2C19 GENE WHILE PEPTIC ULCER TREATMENT

SPECIFICITIES OF GENOTYPIC VARIATIONS OF CYP2C19 GENE WHILE PEPTIC ULCER TREATMENT

Klichova F.K, Bukhara State Medical Institute named after Abu Ali ibn Sino

Musayeva D.M. Bukhara State Medical Institute named after Abu Ali ibn Sino

Resume

This article presents the results of researches of patients with peptic ulcer disease living in the Bukhara region by genotypic accessories for the CYP2C19 gene. It was found that in all genotypic variations of the gene, the main symptoms of peptic ulcer disease and related diseases do not differ much from each other.

Key words: CYP2C19 gene, variations of CYP2C19, peptic ulcer disease, symptoms of peptic ulcer disease.

First page

206

Last page

211

For citation: Klichova F.K,  Musayeva D.M. Specificities of genotypic variations of cyp2c19 gene while peptic ulcer treatment //New Day in Medicine 2(34/1)2021 206-211 https://cutt.ly/JbNMo5n

LIST OF REFERENCES

  1. Arvanitidis K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // К. Arvanitidis, G. Ragia, M. Iordanidou et al. // Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 – 426.
  2. Dawood S. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy. Cancer Invest. 2009. Oct. Vol.27, №8. P. 809-815.
  3. Efrén Martínez-Quintana, Fayna Rodríguez-González, José María Medina-Gil, Paloma Garay-Sánchez, Antonio Tugores // Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo. Medicina Clínica. Volume 149. Issue 6. 2017. Pages 235-239.
  4. Gaikovitch E.A., Cascorbi I., Mrozikie-wicz P.M., Brockmöller J., Frötschl R., Köpke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population//Eur. J. Clin. Pharmacol. 2003, Aug. Vol.59, №4. P. 303-312.
  5. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response //Clin. Pharmacol. Ther. 2009, Apr. Vol.85, №4. P. 426-430.
  6. Isakov V.A. Farmakogeneticheskiy analiz metabolizma i klinicheskoy effektivnosti ingibitorov protonnogo nasosa / V. A. Isakov // Klin. farmakol. ter. 2003. № 1. S. 32 – 37.
  7. Ivashkin V.T., Mayev I.V., Tsar’kov P.V., Korolev M.P., Andreyev D.N., Baranskaya Ye.K., Burkov S.G., Derinov A.A., Yefetov S.K., Lapina T.L., Pavlov P.V., Pirogov S.S., Tkachev A.V., Trukhmanov A.S., Fedorov Ye.D., Sheptulin A.A. Diagnostika i lecheniye yazvennoy bolezni u vzroslykh (Klinicheskiye rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii, Rossiyskogo obshchestva kolorektal’nykh khirurgov i Rossiyskogo endoskopicheskogo obshchestva) //  Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2020. Vyp. 30. № 1. S. 49-70.
  8. Ieiri I., Higuchi S. Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant  drugs//Yakugaku Zasshi. 2009, Feb. Vol.129, №2. P. 231-235.
  9. Kantemirova B.I., Griganov V.I., Dubina D.SH., Aliyeva Z.G. Polimorfizm gena CYP2C19 u detey, prozhivayushchikh v astrakhanskom regione. //Meditsinskiy vestnik Bashkortostana. Tom 7 №4 2012. 29-32 S.
  10. Kitayeva Ye. Yu., Shprakh V.V., Mirzayev K.B., Ryzhikova K.A., Shuyev G.N., Sozayeva Zh.A., Pimenova Yu.A., Kogay V.V., Sychev D.A. Chastota polimorfizmov genov CYP2C19 i ABCB1, assotsiirovannykh s izmeneniyem antiagregantnogo deystviya klopidogrela, u russkikh i buryat. //Sibirskoye meditsinskoye obozreniye. 2018. №3 43-50 S.
  11. Kukes V.G. Metabolizm lekarstvennykh sredstv: kliniko-farmakologicheskiye aspekty. – /M.: Reafarm, 2004. – S. 113-120.
  12. Klichova F.K., Ochilova G.S. Znacheniye gena MDR-1 farmakoterapii. Sbornik tezisov II Vserossiyskoy nauchno- prakticheskoy konferentsii s mezhdunarodnym uchastiyem. //Bezopasnost’ farmakoterapii: NOLI NOCERE!  g. Kazan’, 16 maya 2019 g. S. 47
  13. Korochanskaya N.V., Durleshter V.M., Serdyuk A.A. Psikhoemotsional’nyy status u patsiyentov s yazvennoy bolezn’yu dvenadtsatiperstnoy kishki, oslozhnennoy sub i dekompensirovannym stenozom // Eksperimental’naya i klinicheskaya gastroenterologiya.  2019. Vyp. 169. № 9. S. 38-44.
  14. Мiguel A. López-García, Iris A. Feria-Romero, Héctor Serrano, Darío Rayo-Mares, Pietro Fagiolino, Marta Vázquez, Consuelo Escamilla-Núñez, Israel Grijalva, David Escalante-Santiago, Sandra Orozco-Suarez // Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological Reports. Volume 69. Issue 3. 2017. Pages 504-511
  15. Musayeva D.M., Ochilov A.K., Ochilova G.S. Korrektsiya farmakometaboliziruyushchey funktsii pecheni antioksidantami //Dostizheniya nauki i obrazovaniya. – 2018. №.10 (32).
  16. Molchanova A.R., Dolgushina A.I., Seljanina A.A. Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy // Experimental and Clinical Gastroenterology. 2020. №6. С.82-87.
  17. Nebert D.W., Dalton T.P. The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006. Dec; 6(12):947-60.
  18. Ochilov A.K. Vazhnost’ tsitokhromov Р450 dlya gastroenterologii //New day in medicine – 2020. – №2 (30/2). – S. 57-59.
  19. Ochilova G.S. Kharakteristika glikoproteina-Р kak belka transportera lekarstvennykh veshchestv  // New day in medicine. – 2020. – №2 (30/2). – S. 60-63.
  20. Ochilov А.К, Musaeva D.M., Features of cyp2c19 gene for individualized pharmacotherapy//New Day in Medicine 1(29)2020 62-65 https://cutt.ly/JbSmwZ4


file

download